‘Unprecedented’ results in AZ’ late-stage Lynparza trial
admin 3rd June 2019 Uncategorised 0The results were announced at the 2019 ASCO meeting. More: ‘Unprecedented’ results in AZ’ late-stage Lynparza trial Source: News
read more
The results were announced at the 2019 ASCO meeting. More: ‘Unprecedented’ results in AZ’ late-stage Lynparza trial Source: News
read moreThe closures are directly affecting smaller practices, with nine out of 10 practices that closed serving fewer than 5,000 patients. More: GP surgery closures hit ‘all-time-high’ last year Source: News
read morePrevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors. More: NICE recommendation for MSD’s Prevymis after re-evaluation Source: News
read moreCHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology annual meeting—and doing it in some of the toughest-to-treat cancers out there. And it wasn’t going to stop this
read moreCHICAGO—Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they argue today’s new data—showing the med cut the risk of death by a third—complement the evidence they’ve already generated. More: ASCO: Pfizer, Astellas' Xtandi racks
read moreLast month, Merck revealed that its Keytruda had run into more trouble in stomach cancer, a disease that’s given it difficulty in the past. And it shared the details of that stumble Saturday. More: ASCO: Merck details Keytruda's second stomach cancer
read more© 1994 - 2026 B.M. Pharmaceuticals